Artificial Intelligence in Model‐Informed Drug Development: Augmentation, Acceleration, and Regulatory Preparation
Open Access
- 7 September 2026
- journal article
- perspective
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (9) , e70727
Abstract
The convergence of MIDD and AI represents a natural evolution from established quantitative frameworks toward a broader, more powerful computational toolbox that can address persistent MIDD challenges such as high‐dimensional data integration, complex biology, and operational constraints in evidence generation. AI can both enhance traditional MIDD through hybrid approaches and extend MIDD's horizon to include various AI models. Recent publications of guidance demonstrate the agency's preparation on the acceptance of AI in MIDD.Keywords
This publication has 4 references indexed in Scilit:
- Stochastic Gates for Covariate Selection in Population Pharmacokinetics ModelingCPT: Pharmacometrics & Systems Pharmacology, 2026
- The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to PathwayClinical Pharmacology & Therapeutics, 2024
- Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use AuthorizationClinical Pharmacology & Therapeutics, 2024
- Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot ProgramClinical Pharmacology & Therapeutics, 2021